|
1) Best Doctor in America, Castle Connolly Medical, Ltd, 2006 and 2008.
2) Book Chapter: Wagner TD, Javle M, Yang GY,. Esophageal Tumors: Principles & Practice, Demos Medical Publishing, Inc, 2009 (Chapter 22)
3) Editorial Board
3a) Gastrointestinal Cancer Review Letters
3b) U.S. Chinese Journal of Lymphology and Oncology
4) GI Abstract Review Panel
ASTRO Annual Meeting and Program Committee, 2007-2009
Canadian Radiation Oncology Association (CARO) Annual Meeting, 2009
5) Moderator
Ano-Rectal and Esophagus Scientific Session, ASTRO 50th Annual Meeting, Boston, MA, 2008
6) Committee Member
Writing committee, National Comprehensive Cancer Network (NCCN) Esophageal and Gastric Guideline Panels, 2007-present
7) Annual Meeting and Scientific Program Committee of the Education Council, ASTRO 2008-present
8) Media Interviews
Abdominal radiation may affect kidneys, ASTRO Annual Meeting, Boston, Renal and Urology News, Sept 2008
Phase III trial of adjuvant capecitabine/cisplatin vs capecitabine/cisplatin/RT in resected gastric cancer with D2 nodal dissection (ARTIST trial): safety analysis ASTRO/ASCO GI Cancer Symposium, San Francisco, HemOnc Today, Jan 2009
Final safety findings from a randomized phase III trial of preoperative FU-based chemoradiation +/- weekly oxaliplatin as neoadjuvant therapy for patients with locally advanced rectal cancer: The STAR (Studio Terapia Adiuvante Retto)-01 randomized trial, ASTRO/ASCO GI Cancer Symposium, San Francisco, HemOnc Today, Jan 2009
9) Publications
Shaukat A, Mortazavi A, Demmy T, Nava H, Wilkinson N, Yang G, Kepner J, Javle M, Should preoperative endoscopy (EGD) be performed routinely for esophageal cancer patients after chemo-radiation treatment? Disease of the Esophagus. 2004;17:129-135
Nallapareddy S, Wilding G, Yang GY et al, Chemoradiation is a tolerable therapy for older adults with esophageal cancer. Anticancer Res. 2005;25:3055-3060
Tripp P, Malhotra H, Javle M, Shaukat A, Russo R, DeBoer S, Podgorsak M, Nava H, Yang GY. Risk of cardiac complications following neoadjuvant chemoradiation for esophageal cancer. Disease of the Esophagus. 2005;18:400-407
Javle MM, Nwogu CE, Donohue KA, Iyer RV, Brady WE, Khemka SV, Smith JL, Demmy TL, Yang GY, Nava HR. Management of locoregional stage esophageal cancer: A single center experience. Disease of Esophagus. 2006;19(2):78-83
Javle M, Ailawadhi S, Yang GY et al. Palliation of malignant dysphagia in esophageal cancer: A literature-based review. The Journal of Supportive Oncology. 2006:4:8:365-373
O'Connor BM, Agrawal A, Lombardo JC, Nwogu CE, Iyer RV, Yang GY, Nava HR, Javle MM. Concurrent oxaliplatin, 5-fluorouracil, and radiotherapy for the treatment of locally advanced esophageal carcinoma: A single center experience. Cancer Journal. 2007:13(2):119-124
Yang GY, Wagner TD, Thomas CR. The role of positron emission tomography in esophageal cancer, Gastrointestinal Cancer Research. 2008:2(1):3-10
Javle M, Yang GY, Review: Neoadjuvant chemoradiotherapy and chemotherapy improve survival in operable esophageal cancer, American College of Physcian Journal Club. 2007 Jul-Aug;147:19
Hazard L, Yang G, McAleer MF, Hayman J, Willett C, Principles and techniques of radiation therapy for esophageal and gastroesophageal junction cancers, Journal of NCCN, 2008:6(9):870-878
Ajani JA. Barthel JS. Bekaii-Saab T. Bentrem DJ. D'Amico TA. Fuchs CS. Gerdes H. Hayman JA. Hazard L. Ilson DH. Kleinberg LR. McAleer MF. Meropol NJ. Mulcahy MF. Orringer MB. Osarogiagbon RU. Posey JA. Sasson AR. Scott WJ. Shibata S. Strong VE. Swisher SG. Washington MK. Willett C. Wood DE. Wright CD. Yang G. NCCN Esophageal Cancer Panel. Esophageal cancer. Journal of the NCCN
|
